August 26, 2016 8:26am

A ‘scorecard’ of public stem, cell, gene and regenerative therapy’s companies …

 


 

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!

By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

 

http://www.regmedinvestors.com/articles/9257